Effect of Afatinib for Lung Cancer on Papillary Thyroid Carcinoma
10.11106/ijt.2022.15.2.131
- Author:
Sang Hwon CHO
1
;
Jin Seok LEE
;
Hyeok Jun YUN
;
Yong Sang LEE
;
Hang-Seok CHANG
Author Information
1. Yonsei University College of Medicine, Thyroid Cancer Center, Seoul, Korea
- Publication Type:C A S E REPO RT
- From:International Journal of Thyroidology
2022;15(2):131-134
- CountryRepublic of Korea
- Language:English
-
Abstract:
Papillary thyroid carcinoma is the most common type of thyroid cancer, for which surgery following preoperative staging and risk assessment is the standard treatment. Afatinib is an orally active irreversible ErbB-family inhibitor that binds to the kinase domain of epidermal growth factor receptors (EGFRs), HER2, and HER4, and has been approved as monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer with activated EGFR mutations. Recently, we observed an unexpected effect of afatinib administered to treat lung cancer on untreated papillary thyroid carcinoma.
